Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11222
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKelley, Peter Gen
dc.contributor.authorGao, Weien
dc.contributor.authorWard, Peter Ben
dc.contributor.authorHowden, Benjamin Pen
dc.date.accessioned2015-05-16T00:48:39Z
dc.date.available2015-05-16T00:48:39Z
dc.date.issued2011-03-02en
dc.identifier.citationThe Journal of Antimicrobial Chemotherapy 2011; 66(5): 1057-60en
dc.identifier.govdoc21393156en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/11222en
dc.description.abstractThe aim of this study was to establish the relationship between reduced vancomycin and daptomycin susceptibility among Australasian vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA) isolates from patients never exposed to daptomycin.Forty-seven stored clinical isolates of hVISA/VISA collected before November 2008 from around Australia and New Zealand were selected. Daptomycin and vancomycin MIC testing was performed using broth microdilution (BMD) and Etest methods. Daptomycin population analysis was performed on a subset of isolates.The percentage of daptomycin non-susceptible isolates was 0% for vancomycin-susceptible S. aureus (VSSA) (Etest and BMD), for hVISA it was 26% by Etest and 15% by BMD, and for VISA 62% by Etest and 38% by BMD. Population analysis profile testing demonstrated daptomycin heteroresistance among the hVISA and VISA strains tested.This is the highest rate of daptomycin non-susceptibility reported among hVISA isolates to date. Clinicians should exhibit caution when using daptomycin in situations where serious hVISA or VISA infection is a possibility.en
dc.language.isoenen
dc.subject.otherAnti-Bacterial Agents.pharmacology.therapeutic useen
dc.subject.otherAustraliaen
dc.subject.otherDaptomycin.pharmacology.therapeutic useen
dc.subject.otherDrug Resistance, Bacterialen
dc.subject.otherHumansen
dc.subject.otherMicrobial Sensitivity Testsen
dc.subject.otherNew Zealanden
dc.subject.otherStaphylococcal Infections.drug therapy.microbiologyen
dc.subject.otherStaphylococcus aureus.drug effects.isolation & purificationen
dc.subject.otherTreatment Failureen
dc.subject.otherVancomycin.pharmacology.therapeutic useen
dc.titleDaptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.en
dc.typeJournal Articleen
dc.identifier.journaltitleThe Journal of antimicrobial chemotherapyen
dc.identifier.affiliationDepartment of Microbiology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1093/jac/dkr066en
dc.description.pages1057-60en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/21393156en
dc.type.austinJournal Articleen
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptMicrobiology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

8
checked on Jan 29, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.